PharmaLundensis AB Logo

PharmaLundensis AB

Develops treatments for heavy metal toxicity and serious respiratory illnesses.

PHAL | SPGR

Overview

Corporate Details

ISIN(s):
SE0003359710 (+5 more)
LEI:
54930082I88D5N3GQ506
Country:
Sweden
Address:
Scheelevägen 22, 223 63 Lund
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

PharmaLundensis AB is a pharmaceutical research company that develops treatments for diseases with significant unmet needs. The company's primary project is PHAL-501, a drug designed to bind and excrete heavy metals like mercury, lead, and cadmium from the body. PHAL-501 is intended to act within the intestine, capturing toxins before they are absorbed into the bloodstream, thus offering a potentially safe and effective treatment for heavy metal toxicity. In addition to this focus, the company is also involved in developing therapies for serious respiratory illnesses, such as chronic obstructive pulmonary disease (COPD).

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all PharmaLundensis AB filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for PharmaLundensis AB

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for PharmaLundensis AB via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2025-03-11 Tord Staffan Håkan Skogvall Other Buy 2,337 1,986.45 SEK
2025-01-17 SkåneÖrnen AB Other Buy 121,700 96,143.00 SEK
2025-01-17 Tord Staffan Håkan Skogvall Other Buy 10,958 7,999.34 SEK
2024-10-14 SkåneÖrnen AB Other Buy 49,370 19,748.00 SEK
2024-10-09 Tord Staffan Håkan Skogvall Other Buy 27,936 10,336.32 SEK
2024-09-26 SkåneÖrnen AB Other Buy 63,000 29,610.00 SEK
2024-09-20 Bo Wennergren Other Buy 60,000 27,600.00 SEK

Peer Companies

Company Country Ticker View
A holding company driving regional growth by supporting construction, HR, and nursing care businesses.
Japan 7369
Mendus Logo
Developing immunotherapies using dendritic cells to prevent cancer recurrence and improve survival.
Sweden IMMU
Develops AI-driven, glasses-free 3D holographic displays for the defense sector.
United States of America N/A
MicroAd,Inc. Logo
Data-driven marketing tech providing DSP and SSP solutions for digital advertising.
Japan 9553
Microwave Chemical Co., Ltd. Logo
Innovating chemical and metal processing with an eco-friendly microwave platform.
Japan 9227
A think tank providing research, consulting, and ICT solutions to public & private sectors.
Japan 3636
Modalis Therapeutics Corporation Logo
Develops epigenome editing therapies for genetic muscular, heart, and CNS disorders.
Japan 4883
Model Solution Co., Ltd. Logo
One-stop prototyping & low-volume production for IT, electronics, and medical hardware.
South Korea 417970
Modus Therapeutics Holding AB Logo
Developing sevuparin, a polysaccharide for sepsis, septic shock, and chronic inflammation.
Sweden MODTX
Molecure S.A. Logo
Develops first-in-class small molecule drugs for oncology and inflammatory/fibrotic diseases.
Poland MOC

Talk to a Data Expert

Have a question? We'll get back to you promptly.